Clinical controversies in thrombolytic therapy for the management of acute pulmonary embolism.

Pharmacotherapy

Department of Pharmacy, University Medical Center Brackenridge, Seton Family of Hospitals, Austin, Texas 78703, USA.

Published: February 2012

Acute pulmonary embolism is a common complication in hospitalized patients, spanning multiple patient populations and crossing various therapeutic disciplines. Due to the heterogeneous clinical manifestations, the selection of management strategies for patients with acute pulmonary embolism is a challenge for clinicians, and a nuanced understanding of the relevant literature is required. Previous studies that evaluated thrombolytic therapy in patients with acute pulmonary embolism are limited and controversial. Thus, we sought to identify the clinical controversies related to thrombolytic therapy in acute pulmonary embolism and reviewed the recent literature that impacts clinical practice. To apply these controversies into daily clinical practice and decision making, we provide an overview of risk stratification and assessment of pulmonary embolism. Specific areas of controversies that are discussed relate to the impact of thrombolytic therapy on outcomes, specifically in submassive pulmonary embolism, including mortality, composite primary end points, and intensive care unit length of stay. Other controversies relate to the impact of the patient's sex on outcomes, the most safe and effective thrombolytic dose, optimal administration techniques including infusion duration or concurrent anticoagulation, and therapeutic strategies when thrombolytic therapy is unsuccessful. Despite published guidelines and review articles, select aspects of thrombolytic therapy for the management of pulmonary embolism remain controversial; therefore, clinical practice varies from institution to institution and from practitioner to practitioner. When making decisions about the role of thrombolytic therapy in patients with pulmonary embolism, clinicians must be knowledgeable about areas with limited evidence and the therapy's associated risks. In every situation, practitioners must consider the trajectory of the patient's status and the ability to intervene in an appropriate time frame.

Download full-text PDF

Source
http://dx.doi.org/10.1002/PHAR.1051DOI Listing

Publication Analysis

Top Keywords

pulmonary embolism
36
thrombolytic therapy
28
acute pulmonary
20
clinical practice
12
pulmonary
9
embolism
9
clinical controversies
8
thrombolytic
8
controversies thrombolytic
8
therapy management
8

Similar Publications

Intermittent or transient right bundle branch block (RBBB) can occur in various clinical situations but is rarely described in acute pulmonary embolism. We present a unique case involving a 57-year-old male who experienced a syncopal episode during transit. He displayed signs of a transient right bundle branch block (RBBB) and S1Q3T3 on the initial EMS ECG, which reverted to normal ECG later.

View Article and Find Full Text PDF

Importance: Cervical cancer is the fourth most common cancer among women globally and a significant cause of cancer-related deaths. Understanding the impact of cervical cancer diagnosed during pregnancy on maternal, delivery, and neonatal outcomes is crucial for improving clinical management and outcomes for affected women and their children.

Objective: To determine the effects of cervical cancer diagnosed during pregnancy on maternal, delivery, and neonatal outcomes using a population based, American database.

View Article and Find Full Text PDF

Patients with pulmonary embolus (PE) can be stratified into low, intermediate, and high risk based on such factors as hemodynamics and the status of the right ventricle. Low risk patients who meet appropriate criteria can potentially be discharged home with oral anticoagulation, avoiding unnecessary hospitalization and associated complications and costs. However, limited data suggest early discharge of low-risk patients has not gained widespread traction.

View Article and Find Full Text PDF

Background: Venous thromboembolism (VTE), whether pulmonary embolism (PE) or deep vein thrombosis (DVT), is common in patients with COVID-19. Recommendations on systematic screening in the intensive care unit (ICU) are lacking.

Research Question: Is there any clinical benefit of systematic screening for DVT in critically ill patients with severe COVID-19?

Study Design And Methods: Single-center randomized clinical trial (RCT) of COVID-19 cases admitted to the ICU.

View Article and Find Full Text PDF

Background: Venous thromboembolism (VTE) comprises deep vein thrombosis (DVT) and pulmonary embolism (PE). Chronic thromboembolic pulmonary hypertension (CTEPH) typically arises from acute pulmonary embolism. The pathogenesis of them involves multiple risk factors such as genetic predisposition.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!